Skip to main content

Validation of surrogate end points in multiple randomized clinical trials with failure time end points

Buy Article:

$51.00 plus tax (Refund Policy)


Before a surrogate end point can replace a final (true) end point in the evaluation of an experimental treatment, it must be formally ‘validated’. The validation will typically require large numbers of observations. It is therefore useful to consider situations in which data are available from several randomized experiments. For two normally distributed end points Buyse and co-workers suggested a new definition of validity in terms of the quality of both trial level and individual level associations between the surrogate and true end points. This paper extends this approach to the important case of two failure time end points, using bivariate survival modelling. The method is illustrated by using two actual sets of data from cancer clinical trials.

Keywords: Copula model; Failure time end point; Meta-analysis; Surrogate end point; Validation

Document Type: Original Article


Affiliations: 1: Limburgs Universitair Centrum, Diepenbeek, Belgium, 2: International Drug Development Institute, Brussels, Belgium

Publication date: 2001-01-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more